Advanced in Localized Scleroderma

Dr. Flavia V. Castelino

Rheumatology
The General Hospital Corporation
40 2nd Ave, 
Waltham, MA 
Accepting New Patients
Offers Telehealth
Advanced in Localized Scleroderma
The General Hospital Corporation
40 2nd Ave, 
Waltham, MA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Flavia Castelino is a Rheumatologist in Waltham, Massachusetts. Dr. Castelino is rated as an Advanced provider by MediFind in the treatment of Localized Scleroderma. Her top areas of expertise are Scleroderma, Systemic Sclerosis (SSc), Scleroma, and Sjogren Syndrome. Dr. Castelino is currently accepting new patients.

Her clinical research consists of co-authoring 45 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 2 articles in the study of Localized Scleroderma.

Specialties
Rheumatology
Licenses
Internal Medicine in MA
Hospital Affiliations
Newton-Wellesley Hospital
Massachusetts General Hospital
North Shore Medical Center -
Cooley Dickinson Hospital Inc,the
Brigham And Women's Hospital
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
BMC HealthNet
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
CareFirst
  • HMO
  • POS
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Commonwealth Care Alliance
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
Community Health Options
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health New England
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Mass General Brigham Health Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Tufts
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 15 Less Insurance Carriers -

Locations

THE GENERAL HOSPITAL CORPORATION
40 2nd Ave, Waltham, MA 02451
Other Locations
THE GENERAL HOSPITAL CORPORATION
55 Fruit St, Boston, MA 02114

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

A Phase 2 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety and Efficacy of Ifetroban in Patients With Diffuse Cutaneous Systemic Sclerosis (SSc) or SSc-associated Pulmonary Arterial Hypertension (SSc-PAH)
A Phase 2 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety and Efficacy of Ifetroban in Patients With Diffuse Cutaneous Systemic Sclerosis (SSc) or SSc-associated Pulmonary Arterial Hypertension (SSc-PAH)
Enrollment Status: Active_not_recruiting
Publish Date: July 10, 2025
Intervention Type: Drug
Study Drug: Ifetroban
Study Phase: Phase 2
An Extended Access Program to Assess Long-term Safety of Bardoxolone Methyl in Patients With Pulmonary Hypertension
An Extended Access Program to Assess Long-term Safety of Bardoxolone Methyl in Patients With Pulmonary Hypertension
Enrollment Status: Terminated
Publish Date: June 11, 2025
Intervention Type: Drug
Study Phase: Phase 3
A Study of the Efficacy and Safety of Bardoxolone Methyl in Patients With Connective Tissue Disease-associated Pulmonary Arterial Hypertension
A Study of the Efficacy and Safety of Bardoxolone Methyl in Patients With Connective Tissue Disease-associated Pulmonary Arterial Hypertension
Enrollment Status: Terminated
Publish Date: June 04, 2025
Intervention Type: Drug
Study Phase: Phase 3
A Phase 2, Randomized, Placebo-controlled, Double-blind, Open-label Extension Multicenter Study to Evaluate the Efficacy and Safety of Belumosudil (KD025) in Subjects With Diffuse Cutaneous Systemic Sclerosis
A Phase 2, Randomized, Placebo-controlled, Double-blind, Open-label Extension Multicenter Study to Evaluate the Efficacy and Safety of Belumosudil (KD025) in Subjects With Diffuse Cutaneous Systemic Sclerosis
Enrollment Status: Terminated
Publish Date: August 30, 2023
Intervention Type: Drug
Study Drug: Belumosudil (KD025)
Study Phase: Phase 2
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial to Evaluate Efficacy and Safety of Lenabasum in Diffuse Cutaneous Systemic Sclerosis
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial to Evaluate Efficacy and Safety of Lenabasum in Diffuse Cutaneous Systemic Sclerosis
Enrollment Status: Terminated
Publish Date: March 29, 2021
Intervention Type: Drug, Other
Study Phase: Phase 3
A Phase 2 Study to Evaluate Subcutaneous Abatacept vs. Placebo in Diffuse Cutaneous Systemic Sclerosis- a Double-blind, Placebo-controlled, Randomized Controlled Trial.
A Phase 2 Study to Evaluate Subcutaneous Abatacept vs. Placebo in Diffuse Cutaneous Systemic Sclerosis- a Double-blind, Placebo-controlled, Randomized Controlled Trial.
Enrollment Status: Completed
Publish Date: February 17, 2020
Intervention Type: Drug
Study Phase: Phase 2
View 5 Less Clinical Trials

45 Total Publications

Use of Nintedanib for the Treatment of Systemic Sclerosis-associated Interstitial Lung Disease at Expert Scleroderma Centers in the United States.
Use of Nintedanib for the Treatment of Systemic Sclerosis-associated Interstitial Lung Disease at Expert Scleroderma Centers in the United States.
Journal: Annals of the American Thoracic Society
Published: April 10, 2025
Similar Doctors
Advanced in Localized Scleroderma
Dr. Michael R. York
Rheumatology
Advanced in Localized Scleroderma
Dr. Michael R. York
Rheumatology

Evans Medical Foundation Inc

1 Boston Medical Ctr Pl, 
Boston, MA 
 (10.6 miles away)
857-654-1000
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Michael York is a Rheumatologist in Boston, Massachusetts. Dr. York is rated as a Distinguished provider by MediFind in the treatment of Localized Scleroderma. His top areas of expertise are Scleroderma, Systemic Sclerosis (SSc), Scleroma, and Rheumatoid Arthritis (RA). Dr. York is currently accepting new patients.

Advanced in Localized Scleroderma
Dr. Marcin A. Trojanowski
Rheumatology
Advanced in Localized Scleroderma
Dr. Marcin A. Trojanowski
Rheumatology

Evans Medical Foundation Inc

88 E Newton St, Evans 124, 
Boston, MA 
 (10.7 miles away)
617-638-6500
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Marcin Trojanowski is a Rheumatologist in Boston, Massachusetts. Dr. Trojanowski is rated as a Distinguished provider by MediFind in the treatment of Localized Scleroderma. His top areas of expertise are Scleroderma, Systemic Sclerosis (SSc), Scleroma, and Localized Scleroderma. Dr. Trojanowski is currently accepting new patients.

Experienced in Localized Scleroderma
Dr. William F. Harvey
Rheumatology
Experienced in Localized Scleroderma
Dr. William F. Harvey
Rheumatology

Pratt Medical Group Inc

800 Washigton St, 
Boston, MA 
 (10.7 miles away)
617-636-5000
Languages Spoken:
English
See accepted insurances
Accepting New Patients

William Harvey is a Rheumatologist in Boston, Massachusetts. Dr. Harvey is rated as an Advanced provider by MediFind in the treatment of Localized Scleroderma. His top areas of expertise are Rheumatoid Arthritis (RA), Granulomatosis with Polyangiitis, Necrotizing Vasculitis, and Rhizomelic Pseudopolyarthritis. Dr. Harvey is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Castelino's expertise for a condition
ConditionClose
View All 13 Advanced Conditions
View All 34 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile